Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacoeconomic extension study of bifeprunox versus risperidone in schizophrenia (parallel to trial 10200)
2004-002591-42Phase 3Active
- Sponsor
- Lundbeck
- Start
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bifeprunox in schizophrenia (2 arms), sponsored by Lundbeck. Primary endpoint: Sociodemographic data. Started Mar 2012; status: active.
02
Drugs
bifeprunox
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2004-002591-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002591-42.